See more : Feng Hsin Steel Co., Ltd. (2015.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Shin Nippon Biomedical Laboratories, Ltd. (2395.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Shin Nippon Biomedical Laboratories, Ltd., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Alimco Financial Corporation (ALMC) Income Statement Analysis – Financial Results
- IDOX plc (IDOX.L) Income Statement Analysis – Financial Results
- Goodyear India Limited (GOODYEAR.BO) Income Statement Analysis – Financial Results
- Wanbury Limited (WANBURY.BO) Income Statement Analysis – Financial Results
- Innovision FlexTech Corporation (6673.TWO) Income Statement Analysis – Financial Results
Shin Nippon Biomedical Laboratories, Ltd. (2395.T)
About Shin Nippon Biomedical Laboratories, Ltd.
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, provides drug discovery and development services in Japan and internationally. It offers pre-clinical laboratory services, such as good laboratory practice inspections; general and specific toxicity studies; pathological examinations; PK/PD of biopharmaceuticals, immunotoxicity tests, and antibody production; reproductive and developmental toxicity studies; pharmacology and pharmacological efficacy studies; and imaging services. The company also engages in the establishment and validation of analytical methods, analysis of biological samples, and calculation of pharmacokinetic parameters; and provides absorption, distribution, metabolism, and excretion studies using radioisotope-labeled compounds. In addition, it provides site management organization services for clinical trials; clinical contract research organization services; and translational research services, including research and development of nasal delivery systems, nucleic acid adjuvants, and regenerative medicines. The company was founded in 1957 and is headquartered in Tokyo, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 26.45B | 25.09B | 17.75B | 15.11B | 14.56B | 15.66B | 16.60B | 17.24B | 14.75B | 17.84B | 16.93B | 17.15B | 15.27B | 17.37B | 19.05B | 19.54B | 19.65B | 17.29B | 13.81B | 12.30B |
| Cost of Revenue | 12.17B | 12.04B | 8.06B | 7.56B | 6.95B | 9.48B | 11.40B | 12.88B | 12.06B | 11.88B | 11.18B | 12.47B | 11.98B | 12.15B | 12.83B | 12.70B | 11.96B | 10.59B | 8.42B | 8.26B |
| Gross Profit | 14.28B | 13.05B | 9.69B | 7.55B | 7.62B | 6.18B | 5.20B | 4.36B | 2.69B | 5.95B | 5.75B | 4.69B | 3.30B | 5.22B | 6.23B | 6.84B | 7.69B | 6.70B | 5.39B | 4.03B |
| Gross Profit Ratio | 54.00% | 52.00% | 54.58% | 49.99% | 52.30% | 39.45% | 31.35% | 25.28% | 18.24% | 33.37% | 33.96% | 27.32% | 21.58% | 30.06% | 32.68% | 34.99% | 39.13% | 38.75% | 39.03% | 32.81% |
| Research & Development | 1.74B | 683.07M | 425.08M | 392.24M | 400.85M | 339.82M | 518.40M | 600.60M | 815.63M | 739.36M | 747.08M | 577.23M | 979.13M | 699.32M | 699.75M | 652.61M | 706.08M | 1.00B | 729.51M | 755.14M |
| General & Administrative | 1.93B | 1.35B | 1.00B | 835.08M | 859.32M | 953.43M | 906.25M | 1.02B | 1.15B | 1.07B | 1.07B | 1.06B | 1.26B | 1.25B | 1.21B | 1.38B | 1.36B | 1.29B | 975.57M | 893.63M |
| Selling & Marketing | 6.19B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.12B | 1.35B | 1.00B | 835.08M | 859.32M | 953.43M | 906.25M | 1.02B | 1.15B | 1.07B | 1.07B | 1.06B | 1.26B | 1.25B | 1.21B | 1.38B | 1.36B | 1.29B | 975.57M | 893.63M |
| Other Expenses | 261.00M | 15.21M | 191.09M | 211.41M | 119.66M | 97.45M | 38.92M | -69.84M | 168.49M | 162.37M | 170.52M | 194.96M | 486.24M | 389.79M | 542.12M | 229.53M | 176.08M | 29.96M | -20.27M | 14.57M |
| Operating Expenses | 10.12B | 7.80B | 5.49B | 5.02B | 5.39B | 5.35B | 5.90B | 6.15B | 6.55B | 6.59B | 6.47B | 6.11B | 5.56B | 5.30B | 5.13B | 5.52B | 5.15B | 4.83B | 4.00B | 3.76B |
| Cost & Expenses | 22.29B | 19.85B | 13.55B | 12.58B | 12.33B | 14.83B | 17.30B | 19.04B | 18.61B | 18.47B | 17.65B | 18.58B | 17.54B | 17.45B | 17.95B | 18.23B | 17.11B | 15.42B | 12.42B | 12.02B |
| Interest Income | 186.56M | 57.40M | 8.31M | 2.97M | 9.27M | 18.51M | 9.07M | 15.10M | 15.17M | 3.98M | 8.23M | 4.92M | 9.51M | 9.38M | 12.90M | 45.52M | 46.49M | 58.77M | 58.54M | 9.33M |
| Interest Expense | 138.78M | 125.06M | 126.65M | 184.86M | 235.01M | 377.80M | 374.00M | 378.12M | 304.30M | 289.86M | 307.48M | 302.33M | 309.26M | 343.45M | 342.73M | 283.82M | 251.64M | 177.59M | 177.94M | 150.02M |
| Depreciation & Amortization | 1.87B | 1.60B | 1.18B | 1.19B | 1.23B | 1.36B | 1.47B | 1.55B | 1.59B | 1.39B | 1.32B | 1.37B | 1.59B | 1.76B | 1.94B | 1.83B | 1.82B | 1.30B | 919.95M | 836.99M |
| EBITDA | 8.98B | 9.49B | 9.49B | 5.55B | 4.53B | 3.39B | 338.82M | 1.16B | 5.45B | 1.28B | 1.72B | 1.17B | -959.75M | 967.90M | 2.69B | 2.31B | 2.93B | 2.46B | 1.67B | 495.00M |
| EBITDA Ratio | 33.95% | 43.52% | 49.04% | 33.21% | 29.12% | 21.86% | 7.05% | 3.05% | 22.25% | 10.30% | 10.46% | 6.92% | -1.05% | 9.60% | 18.23% | 16.05% | 20.75% | 18.82% | 17.65% | 9.25% |
| Operating Income | 4.16B | 5.25B | 4.20B | 2.53B | 2.23B | 829.80M | -697.47M | -1.79B | -3.86B | -636.30M | -723.77M | -1.43B | -3.05B | -843.66M | 343.83M | 463.94M | 1.59B | 1.13B | 772.20M | -328.97M |
| Operating Income Ratio | 15.74% | 20.90% | 23.64% | 16.74% | 15.30% | 5.30% | -4.20% | -10.39% | -26.19% | -3.57% | -4.28% | -8.33% | -19.96% | -4.86% | 1.80% | 2.37% | 8.07% | 6.51% | 5.59% | -2.68% |
| Total Other Income/Expenses | 2.81B | 2.51B | 3.99B | 1.65B | 834.42M | 820.91M | -810.52M | 1.03B | 7.41B | 237.77M | 819.27M | 916.85M | 187.01M | -295.28M | 67.21M | -264.33M | -729.52M | -149.89M | -197.10M | -162.22M |
| Income Before Tax | 6.97B | 7.76B | 8.18B | 4.18B | 3.06B | 1.65B | -1.51B | -764.69M | 3.55B | -398.53M | 95.50M | -511.24M | -2.86B | -1.14B | 411.05M | 199.61M | 856.11M | 975.89M | 575.10M | -491.19M |
| Income Before Tax Ratio | 26.37% | 30.93% | 46.11% | 27.63% | 21.03% | 10.54% | -9.08% | -4.43% | 24.07% | -2.23% | 0.56% | -2.98% | -18.74% | -6.56% | 2.16% | 1.02% | 4.36% | 5.64% | 4.17% | -3.99% |
| Income Tax Expense | 1.46B | 1.71B | 1.02B | 497.79M | 414.54M | -308.09M | 2.01B | 127.78M | 903.42M | 992.42M | 857.60M | 651.43M | 443.12M | 314.40M | -116.58M | 412.70M | 264.14M | 433.64M | 309.39M | -17.01M |
| Net Income | 5.53B | 6.06B | 7.13B | 3.66B | 2.55B | 1.95B | -3.56B | -915.94M | 2.65B | -1.39B | -754.99M | -1.15B | -3.30B | -1.44B | 534.53M | -205.55M | 599.87M | 543.77M | 267.41M | -472.44M |
| Net Income Ratio | 20.91% | 24.15% | 40.16% | 24.23% | 17.52% | 12.46% | -21.42% | -5.31% | 17.94% | -7.77% | -4.46% | -6.72% | -21.63% | -8.30% | 2.81% | -1.05% | 3.05% | 3.15% | 1.94% | -3.84% |
| EPS | 132.86 | 145.57 | 171.21 | 87.96 | 61.26 | 46.85 | -85.41 | -22.18 | 66.52 | -34.84 | -20.12 | -33.57 | -96.21 | -43.26 | 16.14 | -6.03 | 17.46 | 15.83 | 8.28 | -29.96 |
| EPS Diluted | 132.86 | 145.57 | 171.21 | 87.96 | 61.26 | 46.85 | -85.41 | -22.18 | 66.52 | -34.84 | -20.12 | -33.57 | -96.21 | -43.26 | 16.14 | -6.03 | 17.46 | 15.83 | 8.28 | -29.96 |
| Weighted Avg Shares Out | 41.63M | 41.63M | 41.63M | 41.63M | 41.63M | 41.63M | 41.63M | 41.29M | 39.78M | 39.78M | 37.53M | 34.34M | 34.34M | 33.34M | 33.10M | 34.10M | 34.34M | 34.34M | 32.29M | 15.77M |
| Weighted Avg Shares Out (Dil) | 41.63M | 41.63M | 41.63M | 41.63M | 41.63M | 41.63M | 41.63M | 41.29M | 39.78M | 39.78M | 37.53M | 34.34M | 34.34M | 33.34M | 33.10M | 34.10M | 34.34M | 34.34M | 32.29M | 15.77M |
Source: https://incomestatements.info
Category: Stock Reports